Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.

Heffler M, Golubovskaya VM, Dunn KM, Cance W.

Cancer Biol Ther. 2013 Aug;14(8):761-72. doi: 10.4161/cbt.25185. Epub 2013 Jun 3.

2.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

3.

A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.

Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM.

Cell Cycle. 2009 Aug;8(15):2435-43. Epub 2009 Aug 1.

4.

A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG.

Carcinogenesis. 2012 May;33(5):1004-13. doi: 10.1093/carcin/bgs120. Epub 2012 Mar 7.

5.

FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.

Heffler M, Golubovskaya VM, Conroy J, Liu S, Wang D, Cance WG, Dunn KB.

Anticancer Agents Med Chem. 2013 May;13(4):584-94.

6.

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.

Golubovskaya V, O'Brien S, Ho B, Heffler M, Conroy J, Hu Q, Wang D, Liu S, Cance WG.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1613-31. doi: 10.1007/s00432-015-1924-3. Epub 2015 Feb 6.

PMID:
25656374
7.

A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG.

J Med Chem. 2008 Dec 11;51(23):7405-16. doi: 10.1021/jm800483v.

8.

Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.

Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM.

Cell Cycle. 2010 Mar 1;9(5):1005-15. Epub 2010 Mar 14.

9.

A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

Zhang J, He DH, Zajac-Kaye M, Hochwald SN.

Cell Cycle. 2014;13(19):3143-9. doi: 10.4161/15384101.2014.949550.

10.

A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.

Golubovskaya VM, Palma NL, Zheng M, Ho B, Magis A, Ostrov D, Cance WG.

Anticancer Agents Med Chem. 2013 May;13(4):532-45.

11.
12.

A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.

Ucar DA, Cox A, He DH, Ostrov DA, Kurenova E, Hochwald SN.

Anticancer Agents Med Chem. 2011 Sep;11(7):629-37.

PMID:
21707510
13.
14.

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, Patel N, Schmitt E, LaGreca S, Jani J, Wessel M, Marr E, Griffor M, Vajdos F.

Cancer Res. 2008 Mar 15;68(6):1935-44. doi: 10.1158/0008-5472.CAN-07-5155.

15.

Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells.

Lee JC, Maa MC, Yu HS, Wang JH, Yen CK, Wang ST, Chen YJ, Liu Y, Jin YT, Leu TH.

Mol Carcinog. 2005 Aug;43(4):207-14.

PMID:
16001424
16.

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, Phillips A, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.

Cancer Biol Ther. 2010 May 15;9(10):778-90.

17.

Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction.

Craig DH, Haimovich B, Basson MD.

Am J Physiol Cell Physiol. 2007 Dec;293(6):C1862-74. Epub 2007 Sep 26.

18.

Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.

Ucar DA, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN.

Anticancer Agents Med Chem. 2013 May;13(4):595-602.

19.

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.

Oncotarget. 2013 Oct;4(10):1632-46.

20.

Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.

Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, Lowrey B, Thomas KS, Bouton AH, Hwang RF, Stelow EB, Parsons JT, Bauer TW.

Mol Cancer Ther. 2011 Nov;10(11):2135-45. doi: 10.1158/1535-7163.MCT-11-0261. Epub 2011 Sep 8.

Supplemental Content

Support Center